Allergy Eye Treatments Prescribed by UK Doctors

Allergic conjunctivitis is an IgE-mediated inflammatory response of the conjunctival mucosa to airborne allergens. It is the most common ocular surface disease, affecting 15-20% of the UK population.

The condition significantly impairs quality of life through persistent ocular itch, tearing, redness, and lid swelling that interfere with reading, screen work, driving, and outdoor activities.

Classification guides treatment approach:

Seasonal allergic conjunctivitis (SAC) accounts for 90% of cases. Symptoms coincide with pollen seasons — tree pollen (February-May), grass pollen (May-July), and weed pollen (June-September).

Bilateral symptoms of itch, watering, redness, and chemosis (conjunctival oedema) are typical. Lid oedema and periorbital darkening ("allergic shiners") may be prominent.

Perennial allergic conjunctivitis (PAC) persists year-round, driven by house dust mite, pet dander, and mould spore exposure.

Symptoms tend to be milder but more persistent than SAC, with chronic low-grade itch and gritty sensation predominating.

Vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) are sight-threatening allergic eye conditions requiring specialist ophthalmological management.

VKC affects children and young adults with giant papillae on the upper tarsal conjunctiva and corneal shield ulcers.

AKC occurs in adults with atopic dermatitis and can cause corneal scarring, cataract, and keratoconus.

Pathophysiology mirrors that of allergic rhinitis: allergen cross-links IgE on conjunctival mast cells, triggering degranulation and release of histamine, tryptase, prostaglandins, and leukotrienes.

The early phase (minutes) produces itch, vasodilatation, and increased vascular permeability.

The late phase (4-24 hours) involves eosinophil and T-cell recruitment, causing sustained redness and mucoid discharge.

Key differential diagnoses to exclude:

• Bacterial or viral conjunctivitis (purulent or watery discharge, often unilateral)
• Dry eye syndrome (burning rather than itch, worse with screen use)
• Contact lens-related giant papillary conjunctivitis
• Uveitis (pain, photophobia, reduced vision — urgent ophthalmology referral)
• Acute angle-closure glaucoma (severe pain, haloes, fixed mid-dilated pupil — emergency)

Topical ocular therapy provides direct drug delivery to the affected tissue, achieving high local concentrations with minimal systemic absorption.

NICE and the College of Optometrists recommend a stepwise approach.

Dual-action agents (antihistamine + mast-cell stabiliser) are the preferred first-line prescription option:

Olopatadine 0.1% (Opatanol) is the most widely prescribed dual-action eye drop.

It blocks H1 receptors (immediate itch relief within 3-5 minutes) and stabilises mast cell membranes (preventing further degranulation). Dosing is one drop in each eye twice daily.

The OHIO study demonstrated superior itch and redness scores compared with both ketotifen and placebo. Well tolerated — stinging on instillation occurs in 5-7% and is transient.

Ketotifen 0.025% (Zaditen) is an OTC dual-action alternative. Efficacy is comparable to olopatadine for mild-moderate SAC.

Available without prescription, making it a useful step before prescription escalation.

Azelastine 0.05% eye drops provide rapid-onset antihistamine activity with some mast-cell stabilising properties. Can be used up to four times daily for more severe symptoms.

Mast-cell stabilisers for prophylactic use:

Sodium cromoglicate 2% (Opticrom) requires dosing four times daily and takes 3-7 days to reach maximal effect as it works by preventing mast cell degranulation rather than blocking released histamine.

Its strength lies in long-term prophylactic safety — it is preservative-free (in single-dose units), safe in pregnancy and breastfeeding, and suitable for children.

Start 2-4 weeks before the expected pollen season for optimal preventive effect.

Nedocromil sodium 2% (Rapitil) is a more potent mast-cell stabiliser with anti-eosinophil activity, dosed twice daily.

Topical corticosteroids (fluorometholone, loteprednol) are reserved for severe SAC or VKC/AKC refractory to standard therapy.

Prescribing requires ophthalmological supervision due to risks of raised intraocular pressure (steroid-induced glaucoma), cataract formation with prolonged use, and increased susceptibility to corneal infection.

Topical NSAIDs (ketorolac 0.5%) reduce ocular itch effectively and avoid steroid risks, but their role is limited to adjunctive use in severe seasonal symptoms.

Practical prescribing tips:

• Refrigerate eye drops before use — cold drops provide additional soothing vasoconstriction
• Wait 5-10 minutes between different eye drops to prevent washout
• Contact lens wearers: remove lenses before instilling drops and wait 15 minutes before reinsertion. Use preservative-free formulations to avoid preservative absorption into soft lenses

Optimal management of allergic conjunctivitis integrates topical therapy with systemic allergy management and allergen avoidance, recognising that ocular symptoms rarely occur in isolation from nasal and systemic allergic disease.

The unified airway-eye-nose approach: Since 60-70% of allergic conjunctivitis patients have concurrent allergic rhinitis, treating both conditions simultaneously improves overall outcomes.

NICE recommends combining topical ocular therapy with intranasal corticosteroids and oral antihistamines based on symptom severity.

Integrated treatment ladder:

• Mild SAC: cold compresses + OTC antihistamine eye drops (ketotifen) + oral antihistamine (cetirizine/fexofenadine)
• Moderate SAC: prescription dual-action drops (olopatadine) + intranasal corticosteroid (fluticasone furoate) + oral antihistamine
• Severe SAC: as above + short-course topical corticosteroid eye drops (ophthalmologist supervision) or oral prednisolone 10-20 mg for 5 days
• PAC: year-round prophylactic sodium cromoglicate or olopatadine + allergen avoidance measures + oral antihistamine PRN

Oral antihistamines and eye symptoms: Second-generation oral antihistamines reduce ocular itch by 40-50% but are less effective for conjunctival injection and chemosis than topical agents.

Fexofenadine 180 mg and cetirizine 10 mg show the best ocular symptom data among oral options.

Allergen immunotherapy: For patients with severe seasonal or perennial allergic conjunctivitis refractory to optimised pharmacotherapy, immunotherapy (subcutaneous or sublingual) targeting the specific allergen provides 30-50% improvement in ocular symptom scores.

Benefit is sustained for years after completion of a 3-5 year course.

Monitoring and referral criteria:

• Refer to ophthalmology if: unilateral eye symptoms, visual disturbance, severe pain, corneal involvement suspected (fluorescein staining positive), or symptoms not responding to 4 weeks of optimised topical therapy
• VKC and AKC always require specialist management due to sight-threatening complications
• Annual review for patients on continuous prophylactic therapy to reassess allergen sensitisation and treatment adequacy

Comorbid dry eye: Chronic allergic conjunctivitis disrupts the tear film, producing secondary dry eye in 30-40% of patients. Preservative-free artificial tears (sodium hyaluronate 0.1-0.

2%) used 4-6 times daily supplement the tear film and improve ocular surface health. They can be used alongside anti-allergy drops with a 5-minute interval.

Environmental control measures specifically targeting ocular allergen exposure complement pharmacotherapy and reduce the total allergen load on the conjunctival surface.

Pollen season eye protection:

• Wrap-around sunglasses reduce pollen deposition on the conjunctiva by 30-50% and simultaneously protect against UV and wind irritation
• Avoid rubbing the eyes — this mechanically degranulates mast cells, intensifying the allergic response. Apply cold compresses (clean flannel soaked in cold water, applied for 10 minutes) to relieve itch without tissue damage
• Shower and wash face (including careful eyelid cleansing) after outdoor exposure to remove pollen trapped in eyelashes and brows
• Keep car windows closed and use recirculated air conditioning during high pollen counts
• Pollen counts peak in early morning and late afternoon — scheduling outdoor activities for midday may reduce exposure

Indoor allergen reduction for perennial symptoms:

• Encase bedding in allergen-proof covers to reduce house dust mite exposure during sleep, when the eyes are in prolonged proximity to bedding
• HEPA air purifiers in the bedroom reduce airborne allergen particles by 40-60%
• Keep pets out of bedrooms to reduce overnight ocular exposure to animal dander
• Damp-dust surfaces rather than dry dusting, which aerosolises settled allergen

Contact lens management during allergy season:

• Daily disposable lenses are preferred — allergen accumulates on reusable lenses even with cleaning
• Consider switching to glasses during peak symptom periods
• Preservative-free lubricating drops maintain comfort and flush allergen from the lens surface
• If using preserved anti-allergy drops, remove lenses before instillation and wait 15 minutes. Preservatives (benzalkonium chloride) are absorbed by soft contact lens materials and cause epithelial toxicity

Cold compress technique: Soak a clean cotton pad in refrigerated saline or cold water, wring gently, and apply to closed eyelids for 5-10 minutes.

This provides immediate vasoconstriction (reducing redness and swelling) and soothes itch. Repeat 3-4 times daily during symptom flares. Disposable pads prevent bacterial contamination — never reuse.

Eyelid hygiene: Chronic allergic conjunctivitis can trigger or exacerbate meibomian gland dysfunction and blepharitis.

Daily lid margin cleaning with a warm compress (40 degrees Celsius for 10 minutes) followed by gentle massage improves meibomian gland secretion and tear film stability.

Screen use during flares: Reduced blink rate during screen work (falling from 15-20/minute to 3-5/minute) exacerbates ocular surface drying and allergen retention.

Practise the 20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds, and consciously blink 10 times.